Peroxisome proliferator-activated receptors.
An exciting and rapidly evolving area in vascular biology and atherosclerosis research over the past 3 years has been the establishment of peroxisome proliferator-activated receptor (PPAR) expression in the vascular and inflammatory cells, and the emerging picture of the roles these ligand-activated nuclear receptor/transcription factors might play in vascular biology and atherosclerosis. Such work is all the more compelling given the ongoing clinical use of PPAR activators in patients. Thiazolidinediones (PPAR-g agonists) are used as insulin sensitizers in diabetic patients known to be at extraordinarily high risk for cardiovascular disease, whereas fibrates (PPAR-a agonists) are used to treat dyslipidemia, particularly in the case of high triglycerides and low high-density lipoprotein cholesterol.
Ziouzenkova
Ouliana
O
Division of Cardiovascular Medicine, Brigham and Women's Hospital, 221 Longwood Avenue, LMRC 307, Boston, MA 02115, USA.
Perrey
Stephane
S
Marx
Niko
N
Bacqueville
Daniel
D
Plutzky
Jorge
J
D001161:Arteriosclerosis / Q000378:metabolism; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism
D005227:Fatty Acids; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors